I agree that from where we are now, uplisting seems far away.
However, this PR came after the Shareintel PR. It's not like they announced this as an expected milestone when we were still at .10 right after the heart trial results came out.
With a new financing deal and institutional investors starting to bite, it's not crazy to have a big correction this year from our severe undervaluation.